Pfizer rolls out at-home contraception injection in the U.K.; AdvaMed CEO could step in as PhRMA head;

@FiercePharma: Mylan leverages marketing savvy, price hikes to make EpiPen a go-to med. More | Follow @FiercePharma

@EricPFierce: We all know about drug recalls but who tops the list for device recalls? FierceMedicalDevices feature | Follow @EricPFierce

> Pfizer ($PFE) nabbed U.K. approval to market its three-month contraception injection for women to use at home. Story

> AdvaMed CEO Steve Ubl will likely succeed John Castellani as head of pharma industry trade group PhRMA. Article

> GlaxoSmithKline ($GSK) got an EU recommendation for its asthma med Nucala (mepolizumab). Statement

> AstraZeneca ($AZN) is planning to roll out data on its cancer drugs including Lynparza at the upcoming European Cancer Congress (ECC) in Vienna, Austria. More

> Nestle is expanding its global footprint with a new skin healthcare products factory in Brazil. Story

> Keryx Biopharmaceuticals ($KERX) scored EU approval for its Fexeric to treat hyperphosphatemia in adults with chronic kidney disease. Statement

Medical Device News

@FierceMedDev: ICYMI: LabCorp, China's Fosun Pharma, lead Asia-heavy $15B investment in Ativa Medical. FierceDiagnostics Item | Follow @FierceMedDev

@VarunSaxena2: Four key medical device recalls of 2015. Feature | Follow @VarunSaxena2

@EmilyWFierce: Human Longevity joins with South African insurer for $250 exome sequencing service. FierceDiagnostics story | Follow @EmilyWFierce

> Stealth surgical robotics startup from Intuitive Surgical co-founder raises $150M. More

> EU regulators crack down on Brazilian devicemaker for implant safety scare. Story

> St. Jude launches new patient-monitoring interface for CardioMEMS heart failure monitor. Article

Biotech News

@FierceBiotech: GlaxoSmithKline's asthma injection heads for EU approval. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: BIO boots Martin Shkreli's Turing out after pricing controversy erupts. Article | Follow @JohnCFierce

@DamianFierce: Hard to believe but the pope just described biotech valuations as "stretched." | Follow @DamianFierce

> Next-gen oncolytics upstart Replimune grabs a $30M transatlantic venture round. Report

> Concert Pharma's CF drug tops Vertex's top-seller in early study. Story

> GlaxoSmithKline's asthma injection heads for EU approval. Article

Vaccines News

> IDRI, Wellcome Trust to take tuberculosis jab to PhIIa in South Africa. Story

> Inovio-led team picks up $24M from DARPA to develop Ebola vaccine, treatments. Report

> Serum Institute sets out for dengue fast track. Article

> Scripps Florida nets 4-year, $6M grant from Gates Foundation for HIV vaccine. Story

> Advaxis reports 'encouraging' PhII cervical cancer vaccine data. More

CRO News

> U.K. CRO Venn buys up another contractor. Item

> ShangPharma plots a $60M splash for biologics R&D in China. Story

> German CRO cozies up to Bayer at its Berlin R&D hub. More

> Covance plots a deeper dive into manufacturing. Story

> BioClinica reaches into regulatory affairs with its latest buy. Article

Pharma Manufacturing News

> World's largest reinsurer ready to insure against FDA actions. Report

> Sun Pharma recalls more than 216,000 bottles after label leaches chemical. News

> Aesica plant to get power from biomass plant. More

> Mayne kicks off work on new $65M North Carolina plant. Story

> Pfizer finds buyer for Indian plant set to close this month. Article

Pharma Asia News

> Serum Institute of India throttles back on equity sale. Item

> China-focused RuiYi starts PhI in China on autoimmune candidate RYI-008. News

> HK-listed Lee's Pharmaceutical branches out further with Armetheon deal. More

> Japan's MHLW lines up about 50 candidates for fast-track 'sakigake' process. Story

> Australian subsidies for newer drugs go begging as companies avoid paper chase. Article

And Finally… Weight loss surgery could be a cost-effective way of lowering blood sugar for many diabetics, according to a new study. Article

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.